Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

Share

July 2020; 7 (4) Clinical/Scientific NotesOpen Access

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy

Christoph Mahler, Michael Andrews, Sian M. Henson, Sharmilee Gnanapavan
First published May 20, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000756
Christoph Mahler
From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Andrews
From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sian M. Henson
From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharmilee Gnanapavan
From the Department of Neurosciences (C.M., M.A., S.G.), the Royal London Hospital, Barts Health NHS Trust; and William Harvey Research Institute (S.M.H., S.G.), Barts & the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
Christoph Mahler, Michael Andrews, Sian M. Henson, Sharmilee Gnanapavan
Neurol Neuroimmunol Neuroinflamm Jul 2020, 7 (4) e756; DOI: 10.1212/NXI.0000000000000756

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
405

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Progressive multifocal leukoencephalopathy (PML) secondary to John Cunningham (JC) virus infection remains as yet an untreatable viral infection. Plasmapheresis, adoptive T-cell therapyies, and immune reconstitution strategies have all been used with variable success. Cortese et al.1 showed that pembrolizumab, a programmed cell death protein-1 (PD-1) checkpoint inhibitor, increases CD4+ and CD8+ activities and thereby reduces JC viral load. Five of their 8 patients did well, but the remainder, despite effective PD-1 suppression, failed to establish an anti–JC virus T-cell response. Recently, Kuepper et al.2 published a case of primary immunodeficiency with PML who demonstrated a dramatic reduction in PD-1 expression with pembroluzimab, but the patient still died.

Here, we propose that treating the initial lymphopenia before targeting PD1 expression on T-cells is more effective in clinical outcomes. We used the IL-2 therapy to boost the T-cell CD4/CD8 populations before treatment with pembrolizumab.3

Case 1

A 33-year-old woman presented with progressive cerebellar syndrome on a 4-month history of stage IV diffuse large cell B lymphoma (DLBCL, stage IV) and chemotherapy with rituximab-cyclophophamide, doxorubicin hydrochloride, pncovin, prednisolone (6 cycles) and intrathecal methotrexate (4 cycles). Over the course of 2 weeks, she developed progressive gait ataxia, with multiple falls, and dysarthria. A brain MRI revealed a T2/fluid-attenuated inversion recovery hyperintense lesion in the cerebellar peduncle, and PML was confirmed after brain biopsy with JC virus–positive oligodendrocytes (SV40 staining and RNASeq) and CSF (JC virus DNA 449 copies/mL). Initially, the patient received granulocyte-colony stimulating factor without improvement in CD4+ and CD8+ counts. Subsequently, IL-2 was commenced as a subcutaneous (s.c.) injection (IL-2: 50,000 units/m2, followed by 1 million units/m2 maintenance dose, figure, A). After 5 days, IL-2 was switched to IV infusions (same dose). During the initial applications, an infusion reaction with increased temperatures and confusion occurred, and no severe side effects were observed. A total of 19 doses of IL-2 followed by one dose of pembrolizumab (200 mg, iv) were administered based on elevated PD-1+ CD4+70% and PD-1+ CD8+79% compared with age-matched controls of PD-1+ CD4+ 8% and PD-1+ CD8+ 10%. On treatment, her T-cell counts increased (CD4+ before: 24/μL, after: 77/μL; CD8+ before: 4/μL, after: 89/μL) and her JC virus titer decreased to 98 copies/mL. Her MRI (figure, C) and her clinical symptoms stabilized; however, unfortunately, her original lymphoma reoccurred a month later, and a decision was made not to retreat.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Antiviral immune response and PML lesion evolution after treatment with IL2 and pembrolizumab for case 1 and 2

Shown is the percentage of PD-1+ in CD4+ and CD8+ T-cells in blood and the JC virus DNA titer in CSF (A and B) and lymphocyte subpopulations in blood (case 1: A, case 2: B) (C) case 2 PD-1+ % in blood vs age-matched control (control PD-1+) and JC virus DNA titer in the CSF. Evolution of the PML lesion in MRI (D) case 1, (E) case 2, top: T2/FLAIR, middle: T2/FLAIR lesion area pseudocolored in yellow, differential increase (red), differential reduction (green), bottom: B1000 DWI. Treatment bar: brown for IL2 and yellow for PD1. *Marks drop in lymphocyte subpopulations in case 2 secondary to dose escalation of IL-2 to 2.07 million units/m2. JC = John Cunningham; PD-1 = programmed cell death protein-1; PML = Progressive multifocal leukoencephalopathy.

Case 2

A 60-year-old man presented with a frontal lobe syndrome, cognitive impairment, and personality change subsequent to treatment with 6 cycles of R-CHOP for DLBCL (stage IIIS) diagnosed 12 months before presentation. MRI demonstrated a progressive PML lesion in the frontal lobe (figure, D), and the CSF JCV DNA titer was 309 copies/mL. Treatment was initially commenced on daily s.c. IL-2: 50,000 units/m2 for 5 days and subsequently increased to 1million units/m2. On dose increase, he developed fevers, confusion, and tremors, which resolved with dose reduction back down to 50,000 units/m2 and periinfusion paracetamol and chlorphenamine. After 8 days, the route of administration was switched to i.v., then escalated to 1 million units/m2 and later to 2.07 million units/m2. The latter resulted in a sudden drop in lymphocyte subsets, and the dose was quickly reduced back down to 1 million units/m2 leading to recovery (figure, B). A total of 99 doses of IL-2 were given, followed by 2 doses of pembrolizumab (175 mg, iv). JC virus DNA levels decreased and were undetectable by the end of treatment (figure, C). Lymphocyte populations increased (CD4+ before: 245/μL, after: 398/μL; CD8+ before: 192/μL, after: 300/μL; figure, B), and MRI showed stabilization of the PML lesion (figure, D). On discharge, he was fully independent for all activities of daily living.

PML in cases of significant lymphopenia is particularly difficult to manage. The overall immune response is hampered because of the deficient immune cell interactions and a failure to mount an effective T-cell immune response.4,5 Using IL-2 first to boost the native lymphocyte population is a key strategy to mounting an effective immune response to JC virus.3 This can subsequently be consolidated using a PD-1 antagonist, such as pembrolizumab, to maintain the activity. To our knowledge, this is the first report of a combined treatment with IL-2, followed by pembrolizumab for PML.

Indeed, the CD4+ and CD8+ profiles fluctuate with the IL-2 treatments, as do their PD1 expression, suggesting that the artificial boosting of these cell subsets is closely related to the individual injections. Interestingly, there was also favorable improvement of other immune subsets, including CD19 and CD56; CD56 being more robust. Data on the relative distribution and activity of different immune cells are unknown, with CD4+ lymphopenia being considered critical in PML emergence.6 Moreover, sustained expression of PD-1 on their cell surfaces has been linked to T-cell exhaustion.7 It is therefore critical to deploy a dual strategy not only stimulating the intrinsic lymphocyte pool but also sustaining their activity. We found that the PD1 expression in the age-matched healthy controls was much lower and less prone to variation (figure, C). Despite an initial downward trend in PD-1 expression in case 1 after pembroluzimab, the levels did increase again. There is a growing appreciation that although PD-1/PD-L1 therapy can result in dramatic therapeutic responses, treatment is only effective in a subset of patients, and many patients are only partial responders. Indeed, some patients do not respond to initial therapy, whereas others, despite showing a robust initial response to therapy, go on to develop progressive disease. The mechanisms for this resistance are being uncovered, but it is becoming clear that a patient's individual environmental and genetic factors, together with previous treatments create an evolving therapeutic environment that may be in play here.8

Study funding

No targeted funding reported.

Disclosure

C. Mahler, M. Andrews, and S.M. Henson report no disclosures related to this study. S. Gnanapavan: Honoraria/speaker fees from Biogen Idec, Novartis, Merck, Roche, Teva and Neurodiem; and grant funding for UK MS Society, NMSS, Genzyme, Merck, and Takeda. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors would like to thank Professor David Baker, Queen Mary University of London for his helpful comments.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • ↵* These authors contributed equally to this work.

  • The Article Processing Charge was funded by the authors.

  • Received December 11, 2019.
  • Accepted in final form April 6, 2020.
  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Cortese I,
    2. Muranski P,
    3. Enose-Akahata Y, et al
    . Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019;380:1597–1605.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kupper C,
    2. Heinrich J,
    3. Kamm K, et al
    . Pembroluzimab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 2019;6:e628. doi: 10.1212/NXI.0000000000000628.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Gascó AF,
    2. Vericat JM,
    3. Albir MC, et al
    . CP-070 Interleukin-2 treatment of two patients with multifocal progressive leukoencephalopathy associated with hiv infection. Eur J Hosp Pharm 2017;24:A31.
    OpenUrl
  4. 4.↵
    1. Durali D,
    2. de Goër Herve MG,
    3. Gasnault J,
    4. Taoufik Y
    . B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol 2015;6:241.
    OpenUrl
  5. 5.↵
    1. Taoufik Y,
    2. de Goër Herve MG
    . Editorial: immune control of JC virus infection and immune failure during progressive multifocal leukoencephalopathy. Front Immunol 2017;8:1646.
    OpenUrl
  6. 6.↵
    1. Berger JR,
    2. Pall L,
    3. Lanska D et al
    . Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998;4:59–68.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Tumeh PC,
    2. Harview CL,
    3. Yearley JH et al
    . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–571.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Nowicki TS,
    2. Hu-Lieskovan S,
    3. Ribas A
    . Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J 2018;24:47–53.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case 1
    • Case 2
    • Study funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • MRI

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 9 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise